Development of a First-in-class Shared Neo-Antigen Vaccine for the Treatment of Prostate Cancer

Time: 4:45 pm
day: Day Two


• Data to show critical understanding of the tumor microenvironment to determine response to immune checkpoint therapy in combination with cancer vaccines
• Identification of VISTA as a potent inhibitory checkpoint that is predominantly expressed on CD68+ macrophages on PDACs, suggesting that VISTA may be a relevant immunotherapy target for effective treatment of patients with pancreatic cancer